文献类型：期刊文献

中文题名：肝癌与铁死亡的研究进展

英文题名：Research Advancements in Hepatocellular Carcinoma and Ferroptosis

作者：李林俞[1,2];陈鑫[1,2];李红玲[2]

第一作者：李林俞

机构：[1]甘肃中医药大学第一临床医学院,甘肃 兰州;[2]甘肃省人民医院肿瘤内科,甘肃 兰州

第一机构：甘肃中医药大学临床医学院

年份：2022

卷号：12

期号：10

起止页码：9363

中文期刊名：临床医学进展

外文期刊名：Advances in Clinical Medicine

语种：中文

中文关键词：肝癌;席夫碱配体衍生物;铁死亡;P53

摘要：肝细胞肝癌(hepatocellular carcinoma, HCC)是世界范围内最常见的恶性肿瘤之一。最新的数据显示,HCC发病率排位已上升至第六位,死亡率更是高达第三位。我国是一个乙肝大国,肝硬化是乙肝患者的终末期状态,HCC更是导致肝硬化患者死亡的最主要的原因。多年来,关于索拉非尼诱导肿瘤细胞死亡模式的研究层出不穷,过去人们更倾向于认为这种模式是细胞凋亡。然而最新研究已经证实,由索拉非尼诱导肝癌细胞死亡的模式是铁死亡,而不是凋亡。这给我们探索治疗HCC开启了新的研究方向。
In the world, hepatocellular carcinoma (HCC) is one of the most prevalent malignant tumors. Ac-cording to the most recent data, the incidence of HCC has increased to the sixth spot, while the fatal-ity rate has reached the third spot. China has a high hepatitis B prevalence. Hepatitis B patients who have liver cirrhosis have reached the end stage of the disease, and HCC is the primary killer of peo-ple with liver cirrhosis. Numerous researches have been done over the years on the manner of so-rafenib-induced tumor cell death, which was formerly more frequently referred to as apoptosis. Recent research, however, has demonstrated that ferroptosis, as opposed to apoptosis, is the mode of liver cancer cell death brought on by sorafenib. This opens a new research direction for us to ex-plore the treatment of HCC.